Key result
The A/MAY/97 emergency vaccine demonstrated an intra-serotype heterologous potency of 6.5 PD50/dose against challenge with a field isolate from the A/ASIA/G-VII lineage.
Why the study?
Emerging A/ASIA/G-VII lineage foot-and-mouth disease virus poorly matched regional and commercially available vaccines in vitro, prompting assessment of two candidate vaccines against challenge with a representative field virus.
Does the A/MAY/97 emergency vaccine protect cattle against clinical disease when challenged with a heterologous foot-and-mouth disease virus from the A/ASIA/G-VII lineage?
Population
Cattle
Comparison
A/MAY/97 vaccine (full, 1/3, and 1/9 doses) vs A22/IRQ/64 vaccine vs controls
Design
Vaccine challenge and potency test (PD50) experiment
Follow-up
21 days post vaccination
Authors
Loading...
May support candidate FMD vaccines against A/ASIA/G-VII; leaves open field efficacy and broader matching needs.
Does the A/MAY/97 emergency vaccine protect cattle against clinical disease when challenged with a heterologous foot-and-mouth disease virus from the A/ASIA/G-VII lineage?
Effect estimate: 6.5 PD50/dose
A high-potency emergency vaccine can provide cross-protection against clinical disease when challenged with a heterologous strain of the same foot-and-mouth disease virus serotype.
Dekker et al. (2020) studied Foot-and-mouth disease (FMD). A/MAY/97 emergency vaccine vs. Unvaccinated control cattle was evaluated on Intra-serotype heterologous potency (PD50) (6.5 PD50/dose). The A/MAY/97 emergency vaccine demonstrated an intra-serotype heterologous potency of 6.5 PD50/dose against challenge with a field isolate from the A/ASIA/G-VII lineage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: